Dyne Therapeutics grants options to director Lubner

Dyne Therapeutics director David Charles Lubner received a new stock option grant covering 35,152 shares of common stock.

Rhea-AI Filing Summary

Dyne Therapeutics director David Charles Lubner received a new stock option grant covering 35,152 shares of common stock. The option has an exercise price of $17.04 per share and expires on June 4, 2036. All 35,152 underlying shares are scheduled to vest in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to his continued service. After this grant, Lubner holds 35,152 stock options directly. This is a compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 35,152 shares

Grant/Award 1 txn

Insider Lubner David Charles

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	35,152	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 35,152 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Key Figures

Option shares granted: 35,152 shares Exercise price: $17.04 per share Total options after grant: 35,152 options +2 more

5 metrics

Option shares granted 35,152 shares Stock option grant reported June 5, 2026

Exercise price $17.04 per share Stock option (right to buy) for Dyne common stock

Total options after grant 35,152 options Holdings following reported transaction

Expiration date June 4, 2036 Option term end date

Scheduled vesting date Earlier of June 5, 2027 or 2027 annual meeting Vesting condition subject to continued service

Key Terms

Stock option (right to buy), Grant, award, or other acquisition, Annual Meeting of Stockholders

3 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Annual Meeting of Stockholders financial

"the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dyne Therapeutics (DYN) director David Charles Lubner report in this Form 4?

David Charles Lubner reported receiving a stock option grant for 35,152 shares of Dyne Therapeutics common stock. The award is a compensation-related grant, not an open-market trade, and represents new options he now holds directly.

How many Dyne Therapeutics (DYN) shares are covered by Lubner’s new stock options?

The new stock option grant covers 35,152 shares of Dyne Therapeutics common stock. These shares are the underlying securities that Lubner can purchase at the option’s fixed exercise price if and when the options vest and are exercised.

What is the exercise price and expiration date of Lubner’s Dyne Therapeutics options?

The granted stock options have an exercise price of $17.04 per share and expire on June 4, 2036. This means Lubner can buy Dyne Therapeutics shares at $17.04 any time after vesting and before the June 2036 expiration date.

When do David Charles Lubner’s new Dyne Therapeutics options vest?

The options are scheduled to vest in full on the earlier of June 5, 2027 or the date of Dyne Therapeutics’ 2027 Annual Meeting of Stockholders. Vesting is conditioned on Lubner’s continued service through the applicable vesting date.

Is Lubner’s Form 4 transaction in Dyne Therapeutics (DYN) a stock purchase or sale?

The Form 4 reports an acquisition of stock options as a grant, not a market purchase or sale of common shares. The transaction code is a compensation-related grant, so no open-market buying or selling occurred in this filing.

How many Dyne Therapeutics options does Lubner hold after this grant?

Following the reported grant, Lubner holds 35,152 stock options directly. This total reflects the new options acquired in the transaction, which are all linked to Dyne Therapeutics common stock as the underlying security.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 05:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lubner David Charles

(Last) (First) (Middle)

C/O DYNE THERAPEUTICS, INC.

1560 TRAPELO ROAD

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dyne Therapeutics, Inc. [ DYN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$17.04	06/05/2026		A		35,152		(1)	06/04/2036	Common Stock	35,152	$0.00	35,152	D

Explanation of Responses:

1. This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

	/s/ Ron Caponigro, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)